title: Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
authors.forename: Valdir Sabbaga
authors.initials: VS
authors.lastname: Amato
authors.forename: Felipe Francisco
authors.initials: FF
authors.lastname: Tuon
authors.forename: Aleia
authors.initials: A
authors.lastname: Campos
authors.forename: Helio Arthur
authors.initials: HA
authors.lastname: Bacha
authors.forename: Antonio Carlos
authors.initials: AC
authors.lastname: Nicodemo
authors.forename: Vicente
authors.initials: V
authors.lastname: Amato Neto
authors.forename: Maria Aparecida
authors.initials: MA
authors.lastname: Shikanai-Yasuda
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D000981:Antiprotozoal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B